Results 1 to 10 of about 3,975 (165)

Three-step synthetic procedure to prepare dolutegravir, cabotegravir, and bictegravir

Green Chemistry Letters and Reviews, 2022
Dolutegravir, cabotegravir, and bictegravir are three integrase inhibitors, which were used for HIV-1 in the clinic. In this paper, a continuous three-step synthetic strategy was developed to prepare dolutegravir, cabotegravir, and bictegravir in a ...
Yuqi He, Changkuo Zhao, Xianheng Wang
exaly   +4 more sources

A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model [PDF]

Pharmaceutics, 2022
Animal pregnancy models can be useful tools to study HIV antiretroviral safety and toxicity and to perform mechanistic studies that are not easily performed in humans.
Lena Serghides, Chanson J Brumme, Haneesha Mohan   +2 more
exaly   +4 more sources

AI-driven discovery of antiretroviral drug bictegravir and etravirine as inhibitors against monkeypox and related poxviruses [PDF]

Communications Biology
Monkeypox virus (MPXV) caused the 2022–2023 global mpox and the concurrent outbreaks in Africa, disproportionately affecting immunocompromised individuals such as people living with HIV.
Yining Wang, Atabey Ünlü, Xin Wang, Elif Çevrim, Dewy Mae Offermans, Myrthe P. Flesseman, Luca M. Zaeck, Liping Wu, Marcel J. C. Bijvelds, Nadia A. Sam-Agudu, Rory D. de Vries, Karine Raymond, Pengfei Li, Abdurrahman Olğaç, Wenshi Wang, Tunca Doğan, Qiuwei Pan   +16 more
doaj   +3 more sources

Bictegravir and Metformin Drug-Drug Interaction in People with Human Immunodeficiency Virus (HIV)

Infectious Disease Reports, 2023
A drug-drug interaction (DDI) exists between bictegravir and metformin. Bictegravir inhibits renal organic cation transporter-2, leading to increased metformin plasma concentrations.
Anne M. Masich, Lindsey Thompson, Patricia P. Fulco   +2 more
doaj   +2 more sources

RP-HPLC method development and validation for the estimation of Emtricitabine, Bictegravir and Tenofovir alafenamide in bulk and pharmaceutical dosage form

Journal of Taibah University for Science, 2019
A new simple, accurate, precise RP-HPLC [reverse phase high performance liquid chromatography] method was developed for the simultaneous estimation of the Emtricitabine, Bictegravir and Tenofovir alafenamide in pharmaceutical dosage form.
Duvvuri Suryakala, Tej Kumar Kokkirala
exaly   +2 more sources

Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?

HIV/AIDS - Research and Palliative Care, 2023
Jenna E Januszka, Emily N Drwiega, Melissa E Badowski University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USACorrespondence: Melissa E Badowski, Clinical Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, College ...
Emily Drwiega, Jenna Januszka
exaly   +2 more sources

Need for Medication Review and Deprescribing in People Living with HIV: A Longitudinal Observational Study [PDF]

Pharmaceuticals
Background/Objectives: People Living with HIV (PLWH) often have comorbidities require polypharmacy, increasing the risk of adverse events (AEs) associated with drug–drug/drug–supplement interactions (DDIs/DSIs).
Emanuela De Bellis, Danilo Donnarumma, Annarita Pagano, Ines Mazza, Bruno Charlier, Simona Madonia, Alfonso Masullo, Mirella Onofrio, Valentina Fortunato, Anna Maria Spera, Federica Campana, Gianluigi Franci, Flora Salzano, Graziamaria Corbi, Amelia Filippelli, Pasquale Pagliano, Valeria Conti   +16 more
doaj   +2 more sources

Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025 [PDF]

Eurosurveillance
Transmitted integrase inhibitor resistance in newly diagnosed HIV remains rare. We report two cases with baseline resistance to all currently available integrase inhibitors in the Netherlands in 2025.
Marc van der Valk
doaj   +2 more sources

Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort

Diagnostics, 2021
Bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) is a recommended once-daily single tablet regimen for the treatment of people living with HIV-1 (PLWH). We aimed to assess efficacy, safety and tolerability of BIC/FTC/TAF among PLWH,
Alessandro Lazzaro, Elio Gentilini Cacciola, Cristian Borrazzo, Giuseppe Pietro Innocenti, Eugenio Nelson Cavallari, Ivano Mezzaroma, Mario Falciano, Caterina Fimiani, Claudio Maria Mastroianni, Giancarlo Ceccarelli, Gabriella d’Ettorre   +10 more
doaj   +1 more source

Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis

Biomedicines, 2022
To date, therapeutic switches are performed to reduce and prevent toxicity, improve adherence, promote virological control, and save costs. Drug switches are a daily challenge in the management of people living with HIV (PLWH), especially in those with ...
Maria Mazzitelli, Mattia Trunfio, Cristina Putaggio, Lolita Sasset, Davide Leoni, Sara Lo Menzo, Daniele Mengato, Anna Maria Cattelan   +7 more
doaj   +1 more source